期刊文献+

吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌的临床观察 被引量:2

Clinical observation of gemcitabine combined with navelbine in treatment of advanced non-small cell lung cancer
下载PDF
导出
摘要 目的观察吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌的临床效果及毒副反应。方法将108例晚期非小细胞肺癌患者随机分为观察组、对照组G及对照组N,其中,观察组患者给予吉西他滨联合长春瑞滨治疗,对照组G患者给予吉西他滨联合顺铂治疗,对照组N患者给予长春瑞滨联合顺铂治疗。治疗4个周期后,观察各组的临床疗效及毒副反应情况。结果经过4个周期的化疗后,可供评价疗效者共103例,其中,观察组35例,对照组G 34例,对照组N 34例。观察组与对照组的总缓解率及疾病缓解时间差异均无统计学意义(P>0.05);观察组中位生存时间显著长于对照组G和对照组N(P<0.05);观察组出现白细胞下降、血小板下降、红细胞下降、恶心、呕吐及脱发的发生率均明显低于对照组G和对照组N(P<0.05)。结论吉西他滨联合长春瑞滨是晚期非小细胞肺癌的有效姑息治疗方案,可显著延长患者的中位生存时间,小剂量联合应用两种药物可起到与大剂量吉西他滨或长春瑞滨单独应用相同的效果,且可明显降低血液系统及消化道系统不良反应。 Objective To observe the clinical efficacy and toxicity of gemcitabine combined with navelbine in treat- ment of advanced non-small cell lung cancer (NSCLC). Methods 108 cases of patients with advanced NSCLC were randomly divided into observation group,control group G and control group N,while the observation group received gemcitabine combined with vinorelbine treatment,the control group G and control group N only received gemcitabine and navelbine respectively.The clinical efficacy and toxicity of each group after 4 cycles were observe. Results 103 cases were evaluated after 4 cycles,of which 35 cases of the observation group,34 cases of the control group G and 34 cases of the control group N.The overall response rate and remission time between the observation group and the con- trol group had no statistically significance (P〉0.05);the median survival time of the observation group was significantly longer than that of the control group G and control group N with statistically significant (P〈0.05).The rates of toxicity such as leukopenia,thrombocytopenia,decreased red blood cells,nausea,vomiting and alopecia of observation group were significantly lower than that of the control group G and control group N (P〈0.05). Conclusion Gemcitabine combined with vinorelbine is an effective palliative treatment programs for advanced NSCLC significantly,which can significantly prolong the median survival time,with the low-dose combination of the two drugs can play the same effect with high- dose gemcitabine or navelbine alone,and can significantly reduce the blood system and digestive system adverse reac- tions.
作者 崔立献 何洁
出处 《中国当代医药》 2013年第32期84-85,87,共3页 China Modern Medicine
关键词 非小细胞肺癌 吉西他滨 长春瑞滨 联合治疗 Non-small cell lung cancer Gemcitabine Navelbine Combination therapy
  • 相关文献

参考文献10

二级参考文献50

  • 1范若兰.我国肺癌流行病学研究及病因研究概况[J].中国肿瘤,1993,2(11):3-9. 被引量:40
  • 2邓立力,徐玉清,杨宇,于常华.奈达铂联合化疗与顺铂联合化疗方案治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤临床,2005,32(16):941-944. 被引量:23
  • 3潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 4Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine mono-therapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2000;27:75 -80.
  • 5Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non - small cell lung cancer: a two-stage phase II study. Eur J Cancer, 1997, 33:392 -397.
  • 6Veronesi A, Crivellari D, Magri MD, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer, 1996, 32 : 1809 - 1811.
  • 7The elderly lung cancer vinorelbine Italian study group : effects of vinorelbine on quality of life and survival of elderly patients with ad- vanced non-small-cell lung cancer. J Natl Cancer Inst,1999, 91:66 -72.
  • 8Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study(MILES) phase III randomized rial. J Natl Cancer Inst,2003 ,95 :362 -372.
  • 9Bianco V, Rozzi A, Tonini G, et al. Gemcitabine as single-agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer ( NSCLC ) : a phase II study. Anticancer Res 2002 ; 22 : 3053 - 3056.
  • 10Martoni A,Di Fabio F,Guaraldi M,et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol,2001,24 :614 -617.

共引文献35

同被引文献19

  • 1温晓甦,韩爱玲,胡梁南,喻娟.国产与进口吉西他滨在治疗晚期非小细胞肺癌中的成本效果分析[J].实用癌症杂志,2014,29(1):107-108. 被引量:2
  • 2蓝海兵.长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效观察[J].实用中西医结合临床,2006,6(5):8-10. 被引量:4
  • 3李红梅,李海霞,刘克为,王秀美.含顺铂三种化疗方案治疗非小细胞肺癌的临床研究[J].山东大学学报(医学版),2007,45(5):499-502. 被引量:10
  • 4闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913-1915. 被引量:8
  • 5Funai K, Takamochi K, Itaya T,et al. Feasibility study of adju-vant chemotherapy with gemcitabine and split-dose cisplatin forcompletely resected non-small-cell lung cancer[ J]. Lung Cancer,2010,63(5):223-230.
  • 6Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going. [ J ]. Ann Oncol, 2010,21 Suppl7:viil96-198.
  • 7Tibaldi C, Mazzoni E, Arcabasso G, et al. Cisplatin plus gemcit-abine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study [ J ]. Clin Lung Cancer, 2009,10(1) :53-57.
  • 8Funai K, Takamochi K, Itaya T, et al. Feasibility study of adju-vant chemotherapy with gemcitabine and split-dose cisplatin forcompletely resected non-small-cell lung cancer[ J]. Lung Cancer,2010,68(1) :78-83.
  • 9荣荣.HENT1mRNA表达与非小细胞肺癌吉西他滨化疗临床预后的相关性[D].北京:第十五届全国临床肿瘤学大会暨2012年CSC0学术年会,2012.
  • 10Usarai N, Yokoi K, Hasegawa Y, et al. Phase H study of carbo-platin and gemcitabine as adjuvant chemotherapy in patients withcompletely resected non-small cell lung cancer: a report from theCentral Japan Lung Study Group, CjLSG 0503 trial[ J]. Int J ClinOncol, 2010,15(6) :583-587.

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部